Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Posted: CEI and Tag Report, Pre-NOC changes, Duration Document update and Quarterly Review
-
Happy Monday @Manufacturer and @agency
To start your week off on an exciting note, PAAB has a few announcements to share:
- The Quarterly CEI Report and PAAB Tag Report for Q3 have been posted.
- The PAAB Forum Quarterly Review for Q3 has been posted.
- An updated Guidance Regarding Duration of Clinical Trials Used as Reference Support in Advertising has been posted. An annotated version will be posted for 6 months as a reference point of the changes.
- In case you missed last weeks announcement, we have posted an updated approach to the pre-NOC review process that will allow for more pieces to be submitted pre-NOC and prior to the final draft stage of the PM. Learn more here.
Please reach out with comments and questions below.
Have a great week
PAAB -
@jennifer-carroll Yay! Thanks for this!
One remaining question from the previous report: can there be some guidance on why tags were deemed invalid? We were almost looking forward to that following the previous exchange (https://forum.paab.ca/topic/3159/paab-efiles-tag-and-cei-report-q2-2023/4?_=1701119019940) -
Apologies @costeap, I totally let that slip my mind.
Please see the revised page and PDF with the additional information requested in your previous feedback.
Thank you for reminding me.
-
@jennifer-carroll Thank you so much! This should help us learn
